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Abstract
The sodium/bile acid cotransporter NTCP was recently identified as a receptor for hepatitis
B virus (HBV). NTCP is glycosylated and the role of glycans in protein trafficking or viral
receptor activity is not known. NTCP contains two N-linked glycosylation sites and aspara-
gine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a
single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q). HepG2 cells
expressing NTCP with a single glycan supported HBV infection at a comparable level to
NTCP-WT. The physiological function of NTCP, the uptake of bile acids, was also not
affected in cells expressing these single glycosylation variants, consistent with their traffick-
ing to the plasma membrane. However, glycosylation-deficient NTCP (NTCP-N5,11Q)
failed to support HBV infection, showed minimal cellular expression and was degraded in
the lysosome. This affected the physiological bile acid transporter function of NTCP-N5,11Q
in a similar fashion. In conclusion, N-glycosylation is required for efficient NTCP localization
at the plasma membrane and subsequent HBV infection and these characteristics are pre-
served in NTCP carrying a single carbohydrate moiety.
Introduction
The sodium-dependent taurocholate cotransporting polypeptide (NTCP) is an integral mem-
brane glycoprotein that participates in the enterohepatic circulation of bile acids [1]. NTCP is
expressed exclusively at the basolateral membrane of hepatocytes in the liver [2] and mediates
the uptake of glycine/taurine-conjugated bile acids from the portal vein [3–5].
NTCP was recently identified as the bona fide receptor for hepatitis B virus (HBV) and hep-
atitis delta virus (HDV) [6]. HBV and HDV share the same envelope consisting of a membrane
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lipid bilayer into which the small (S), medium (M) and large (L) HBV envelope glycoproteins
are integrated. All three envelop proteins share the S domain, but M and L N-terminally have
an additional preS2 or preS1 and preS2 domain, respectively. L is responsible for the specific
receptor binding via amino acids 157–165 in its pre-S1 domain, which interact with the third
extracellular domain of NTCP [6]. Silencing NTCP expression in HepaRG cells inhibits HBV
and HDV infection and exogenous expression in hepatocyte-derived cell lines HepG2 and
Huh-7 confers permissivity to both viruses [6, 7].
HBV or HDV particle entry into hepatocytes occurs via a multistep process and NTCP
binding is preceded by a low affinity attachment of the virus to cells via the carbohydrate side
chain of heparin sulfate proteoglycans (HSPGs) [8]. Glypican 5 was identified as one of the
HSPGs involved in this process [9]. We recently reported that lentiviral pseudotypes express-
ing HBV glycoproteins infect human hepatoma cells in an NTCP-dependent manner [10] sup-
porting the model that NTCP envelop-protein interaction is sufficient to induce particle
uptake and membrane fusion. Moreover, HBV infection of HepG2-NTCP cells is inhibited in
a concentration-dependent manner by taurine and glycine conjugates of bile acids, the main
substrates for NTCP [11–14], suggesting that bile acids and the HBV pre-S1 domain compete
for NTCP binding. Indeed, a synthetic N-acylated pre-S1 lipopeptide that binds NTCP, Myr-
cludex B, inhibits HBV infection in vitro and in vivo [7, 11, 15–17]. Specific domains of
human NTCP are essential for viral infection and exchange of the first extracellular loop of the
human homolog (specifically amino acids 84–87) into the murine counterpart confers suscep-
tibility to HBV/HDV infection [6]. However, detailed understanding on the structural require-
ments of viral docking to NTCP and the role of carbohydrate moieties in this process is
lacking.
Human NTCP is a multi-pass transmembrane protein that comprises an extracellular N-
terminus and cytoplasmic C-terminal domain [5]. The extracellular N-terminal domain
encodes two N-glycosylation sites at residues N5 and N11 (Fig 1A) [5, 18] and we hypothesize
that these glycosyl moieties regulate NTCP trafficking and localization at the plasma mem-
brane. Carbohydrate moieties of glycoproteins play several roles, such as controlling protein
Fig 1. NTCP structure and mRNA expression. (A) Structure of human NTCP (hNTCP). An HA tag was present at the cell
surface exposed N-terminus. N-linked glycosylation sites are indicated. (B) NTCP mRNA expression in HepG2 cells expressing
NTCP-WT, NTCP-N5Q, NTCP-N11Q or NTCP-N5,11Q analysed by qRT-PCR using primers listed in S2 Table. NTCP
expression values were calculated relative to housekeeping gene H36B4. Data represent mean +/- SD (N = 4).
doi:10.1371/journal.pone.0170419.g001
Effects of NTCP Glycosylation
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folding, stabilizing protein conformation, intracellular and membrane trafficking and interac-
tion with other proteins [19]. We therefore investigated the role of N-glycosylation on NTCP
receptor activity for HBV and bile acid transporter function.
Results
N-glycosyl moieties of NTCP are required for HBV infection
Site-directed mutagenesis of a tagged NTCP open reading frame introduced single or double
substitution of the exofacial Asn residues (N5 and N11) with glutamine, resulted in four con-
structs; NTCP-wild type (WT), NTCP-N5Q, NTCP-N11Q and NTCP-N5,11Q. Expression of
WT and NTCP mutants in HepG2 hepatoma cells showed comparable levels of mRNA as
determined by qPCR (Fig 1A).
We first examined the effect of N-glycosylation on HBV infection of NTCP expressing
HepG2 cell lines. HBV establishes a covalently closed circular DNA (cccDNA) in the nucleus
of infected cells that serves as the transcription template for all viral proteins including secreted
hepatitis B e antigen (HBeAg). Infection was assessed by quantifying cccDNA by qPCR and
measuring HBeAg expression. HBV infection of HepG2 cells expressing WT or single glycan
mutants, NTCP-N5Q and NTCP-N11Q, resulted in comparable levels of cccDNA and HBeAg
expression (Fig 2). However, disruption of both glycosylation sites (NTCP-N5,11Q) prevented
viral infection, both at a multiplicity of infection (MOI) of 100 (Fig 2), and 400 (data not
shown). Since cells expressing NTCP with a single glycan located either at N5 or N11 support
similar levels of infection as the WT transporter molecule, we conclude that a single glycan is
required for HBV infection. Moreover, the location of this glycan is not critical since both N5
and N11 mutants support similar levels of viral infection.
Bile acid uptake affected by NTCP glycosylation pattern
Since HepG2 cells expressing the glycosylation deficient NTCP (NTCP-N5,11Q) variant failed
to support HBV infection, we investigated the capacity of these cells to uptake bile acids. The
Fig 2. HBV infection of wild type and glycosylation deficient NTCP variants. HepG2 cells stably
expressing NTCP-WT, NTCP-N5Q, NTCP-N11Q or NTCP-N5,11Q were infected with HBV. (A) 3 days post
infection, HBeAg production was measured by ELISA. (B) Establishment of HBV infection was determined by
quantification of intracellular cccDNA 3 days post-infection. Values are given as mean +/- sd of two
independent experiments each performed in triplicate. The dotted line represents the values obtained after
infecting parental HepG2 cells that lack NTCP expression. *Significantly different from NTCP-WT values
(p < 0.05).
doi:10.1371/journal.pone.0170419.g002
Effects of NTCP Glycosylation
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single mutants, NTCP-N5Q and NTCP-N11Q, exhibited TCA transport activity comparable
to NTCP-WT. However, NTCP-N5,11Q showed a minimal uptake (Fig 3), suggesting that
NTCP lacking both N-glycosyl moieties is unable to transport bile acids. The reduced uptake
capacity of NTCP-N5,11Q was also observed in Huh-7 cells (S1A Fig). Furthermore, the lim-
ited transport of bile acids by NTCP-N5,11Q was not due to the HA-tag since untagged
NTCP-N5,11Q showed a similar phenotype (S1C–S1E Fig).
NTCP N-glycosylation profile
Since HBV infection and bile acid uptake was defective in HepG2 cells expressing
NTCP-N5,11Q, we investigated the effect of this mutation on protein expression. NTCP-WT
was detected as multiple bands with a molecular mass of 35-60kDa. HepG2 cells expressing
NTCP carrying a single glycan moiety (N5Q or N11Q), displayed a band of 45kDa and
NTCP-N5,11Q migrated around 35kDa (Fig 4A). To test whether the bands at 35-60kDa cor-
respond to differences in N-glycosylation, samples were treated with PNGaseF, that cleaves N-
glycan chains from glycoproteins. This procedure resulted in a near complete shift of NTCP
signal towards +/- 35kDa (Fig 4B), demonstrating that the differences in molecular weight
were due to the addition of N linked glycans on the protein. Since comparable protein
amounts were loaded we conclude that the glycosylation-depleted NTCP variant shows a mod-
est level of protein expression (Fig 4C). Furthermore, similar glycosylation patterns were
observed in HepaRG and Huh7 cells (S1B Fig).
Glycosylation is essential for NTCP localization at the plasma membrane
Since HBV infection and bile acid uptake requires NTCP localization at the plasma membrane,
we anticipated that N-glycosylation would influence NTCP expression at the plasma mem-
brane. Cell surface biotinylation demonstrates that NTCP-WT, NTCP-N5Q, NTCP-N11Q but
Fig 3. Effect of NTCP glycosylation on bile acid transport activity. Taurocholate (TCA) uptake assay in
parental HepG2 cells and those stably expressing NTCP-WT, NTCP-N5Q, NTCP-N11Q or NTCP-N5,11Q.
Cells were incubated for 2 minutes with uptake buffer containing 20 mM taurocholate, spiked with [3H]-
taurocholate. NTCP specific uptake capacity is defined as pmol TCA uptake/well, where the bars represent
the mean +/- sd of three experiments each performed in quadruplicate. *Significantly different from parental
cells and # indicates significantly different from NTCP-WT values (p < 0.05).
doi:10.1371/journal.pone.0170419.g003
Effects of NTCP Glycosylation
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not NTCP-N5,11Q were detected in the plasma membrane fraction (Fig 5A). Notably, the
minority pool of unglycosylated WT protein, migrating at ~35 kDa (Fig 4A) is also not
expressed at the cell surface (Fig 5A). Transferrin receptor was used as loading control and
similar expression levels were detected in all samples. These results were similar when NTCP
cell surface abundance was measured with FITC-labeled Myrcludex B. Myrcludex B, a ligand
based on the pre-S1 domain of HBV-L protein [7, 11, 15], binds NTCP at position 157–165, so
at a certain distance from the glycosyl moieties. NTCP with a single glycan moiety showed a
modest reduction in plasma membrane expression compared to NTCP-WT (Fig 5B). How-
ever, NTCP-N5,11Q showed a significant reduction in plasma membrane expression com-
pared to NTCP-WT (Fig 5B). Altogether, this suggests that glycosylation-depleted NTCP, in
Fig 4. Effect of N-linked glycosylation on NTCP protein expression. (A and B) HA-tagged NTCP was immunoprecipitated (IP) from
lysates of HepG2 cells stably expressing NTCP-WT, NTCP-N5Q, NTCP-N11Q or NTCP-N5,11Q. IP samples were subjected to
immunoblotting for NTCP (using anti-HA-hrp). (B) IP samples were digested with PNGase F for 1h at 37˚C (500 units) prior to immunoblotting
for NTCP. (C) NTCP was quantified by image J and expressed relative to NTCP-WT. Molecular mass is given in kDa on the left-hand side.
Results are mean +/- sd. *Indicates significant different from NTCP-WT (p <0.05).
doi:10.1371/journal.pone.0170419.g004
Effects of NTCP Glycosylation
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Fig 5. Effect of N-linked glycosylation on NTCP plasma membrane expression. Plasma membrane expression was assessed by surface-biotinylation
of parental HepG2 cells or those expressing NTCP-WT, NTCP-N5Q, NTCP-N11Q, NTCP-N5,11Q. (A) Representative immunoblot for NTCP membrane
expression and for the Transferrin receptor (TfR), as a loading control. Molecular mass is given in kDa on the left-hand side. (B) NTCP expression at the
plasma membrane was semi-quantified by Myrcludex-B-FITC intensity. Fluorescence of the parental cells was subtracted before normalization and the net
fluorescence units expressed relative to NTCP-WT. *Indicates significant different from NTCP-WT (p<0,05) (C) Confocal microscopic images of HepG2
cells expressing NTCP-WT or mutant proteins stained with anti-HA (green) and counterstained with Hoechst (blue). Scale bar represents 10μm.
doi:10.1371/journal.pone.0170419.g005
Effects of NTCP Glycosylation
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contrast with NTCP-N5Q and NTCP-N11Q, is not efficiently expressed or targeted to the
plasma membrane.
Since NTCP-N5,11Q showed only minimal plasma membrane expression, we tested
whether this protein was retained in the cytoplasm. As shown in Fig 5C, HepG2 cells express-
ing NTCP-N5,11Q displayed a weak intracellular signal. The NTCP mutants with one glycan
(NTCP-N5Q, NTCP-N11Q), in contrast, showed the same NTCP distribution as NTCP-WT.
Glycosylation-depleted NTCP is rapidly degraded in lysosomes
The low expression levels of NTCP N5,11Q may reflect an enhanced degradation of this vari-
ant. To investigate whether NTCP-N5,11Q was targeted to the proteasome or alternatively
degraded in the lysosome, parental HepG2 cells and those stably expressing NTCP-WT or
NTCP-N5,11Q. were treated with MG132, Bafilomycin or the combination of these two drugs.
The proteasome inhibitor MG132 had no effect on NTCP-N5,11Q expression at the plasma
membrane (Fig 6A) or bile acid uptake (Fig 6B and 6C). However, treatment with Bafilomycin
to prevent degradation of internalized and lysosomally targeted proteins [20], induced an
intracellular accumulation of NTCP (Fig 6A). The increased intracellular signal of NTCP-
N5,11Q following Bafilomycin treatment either alone or in combination with MG132 was not
accompanied by restoration of bile acid uptake activity (Fig 6C). Activity of NTCP-WT was
not affected by Bafilomycin or MG132 (Fig 6C). In conclusion, NTCP-N5,11Q is rapidly endo-
cytosed to be degraded in lysosomes.
Discussion
In the present study, we show that N-linked glycans on NTCP are required for protein expres-
sion, localization, bile acid uptake and NTCP-mediated HBV infection. NTCP binds the preS1
domain of the HBV encoded L protein with high-affinity, and its selective expression at the
basolateral hepatocellular plasma membrane can explain both liver tropism and species speci-
ficity of HBV and HDV.
This study aimed to assess whether the glycosyl-moieties of NTCP itself contribute to virus
infection. Strategies to modulate total cellular glycosylation, such as using tunicamycin would
not be suitable to tackle specifically the contribution of NTCP-bound glycans to HBV infec-
tion. In NTCP, both N5 and N11 are used as glycan-attachments residues and mutating both
amino acids abolished NTCP glycosylation. These amino acids are conserved across multiple
species, including human, mouse, rat, macaca, pongo, and cow and in the related transporter
Slc10a2/ASBT (S3 Table). The data presented here demonstrate that at least one glycan residue
is sufficient for NTCP, plasma membrane localization, bile acid uptake and viral receptor
activity. NTCP-N5,11Q is degraded via the lysosome. This could imply that the glycosylation-
deficient NTCP might be first targeted to the plasma membrane, to be rapidly internalized and
degraded. This model is supported by data showing a low level of bile acid uptake in HepG2
cells expressing NTCP-N5,11Q compared to parental cells. However, treatment with Bafolimy-
cin to inhibit lysosomal degradation did not enhance plasma membrane abundance of the
glycosylation-deficient NTCP, nor bile acid uptake. For several other integral membrane pro-
teins, N-glycosylation is associated with decreased protein stability and absence of glycosyl
moieties can promote degradative pathways [21–23]. Interestingly, multiple transporters that
lack their normal glycosylation, degradation occurs via the proteosomal route, in line with ER-
assisted degradation and impaired trafficking to the plasma membrane [23, 24]. For NTCP the
degradation occurs via a lysosomal fashion, suggesting a post-ER sensing of altered NTCP con-
formation and degradation after entering the endosomal pathway. The small but significant
bile acid uptake seen for NTCP-N5,11Q is in line with (partial) plasma membrane targeting.
Effects of NTCP Glycosylation
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Fig 6. Treatment with Bafilomycin but not with MG132 induces expression of NTCP-N5,11Q. (A,B) Parental HepG2 or cells
expressing NTCP-WT or NTCP-N5,11Q were treated with 0.1% DMSO, Bafilomycin (10nM/24h), MG132 (20μM/6h) or a
combination of Bafilomycin (10nM/24h) and MG132 (20μM/ for the last 6h). (A) Immunofluorescence microscopy of NTCP-WT
and NTCP-N5,11Q. in which NTCP was visualized using anti-HA antibody (green) and Hoechst (blue) was used to visualize the
Effects of NTCP Glycosylation
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The significant uptake of taurocholate that can be detected even while plasma membrane
abundance is minimal also implicates that the NTCP N5,11Q protein is functional. This is sim-
ilar to some other glycoproteins with a transporter function, for example ASCT2, where only
membrane trafficking and not the transport function is affected when glycosylation sites are
mutated [22]. In contrast, for other transporters, for example PEPT1 N-linked glycosylation
does not affect plasma membrane abundance in Xenopus laevis oocytes, but transport kinetics
are lower in the unglycosylated mutant [25].
We did not observe any evidence of HBV infection of HepG2 cells expressing NTCP-
N5,11Q. This could suggest that i) viral entry requires a certain NTCP density at the cell sur-
face, ii) NTCP needs to remain at the plasma membrane sufficiently long to allow efficient
virus docking, or iii) the lysosomal degradation of NTCP is not compatible with its role in
the viral life cycle. Since NTCP-N5,11Q was not detected at the plasma membrane by cell sur-
face biotinylation, we conclude that glycosylation plays an important role in NTCP traffick-
ing. This phenotype makes it impossible to reliably assess the contribution of the NTCP
glycan moieties on viral binding per se to the receptor. However, we can conclude that one
glycan residue is sufficient for bile acid uptake as well as efficient HBV entry. Furthermore,
we established that glycosylation of NTCP, at least one glycan residue, is required for NTCP
localization at the plasma membrane and subsequent bile acid uptake.
Methods
Chemicals and reagents
Hygromycin (merckmillipore), anti-HA HRP (sigma), 3HTaurocholate (Perkin Elmer), Tauro-
cholate (Sigma), MG132 (Z-Leu-Leu-Leu-al) (sigma), Bafilomycin A1 (sigma), DMSO
(VWR), Myrcludex B-FITC (Pepscan), Transferrin receptor (Invitrogen), anti-mouse-HRP
(DAKO).
NTCP glycosylation mutants
Aspargine to glutamine mutations in NTCP constructs [26] were generated using the Quik-
Change1 Site-Directed Mutagenesis Kit (Agilent Technologies). NTCP open reading frames
were cloned into the vector pLenti-PGK-Hygro-DEST (Addgene) using the Gateway LR clo-
nase II enzyme mix (Invitrogen) after initial cloning into pENTR-D-TOPO according to the
manufacturer’s instructions (Life Technologies). All constructs were sequenced to verify they
contained the correct mutation. Primers used to generate the constructs can be found in S1
Table.
Cell culture
Human hepatocellular carcinoma cells (HepG2, from ATCC, VA, USA) and human embry-
onic kidney (HEK293T, from ATCC) cells were cultured in Dulbecco’s modified Eagle’s
medium (Sigma) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin and,
1% Glutamine. Cells were grown at 37˚C in a humidified incubator at a 5% CO2 atmosphere.
nucleus. (B) Results of TCA uptake in parental HepG2 cells (grey) and HepG2 cells expressing NTCP-N5,11Q (black). (C)
Results of TCA uptake in HepG2 cells expressing NTCP-WT (grey) or NTCP-N5,11Q (black). (B,C)The uptake capacity of the
NTCP was determined as pmol TCA uptake/well. Bars represent the mean +/- sd of three independent experiments, each
performed in quadruplicate. *Indicates significant different from DMSO treated (p <0.05). # indicates significant different between
the cell-lines in the same treatment (p<0.05).
doi:10.1371/journal.pone.0170419.g006
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Stable cell-line
HEK293T cells were seeded in 10cm2 plates, 24h before transfection with 3rd generation virus
plasmids, PMD2G, PMDL and PRSV vectors and one of the NTCP constructs. Medium of the
HEK293T cells was harvested and added to HepG2 cells for 6 hours followed by refreshing of
the medium. After 48h, the infected HepG2 cells were selected using Hygromycin (50 μg/ml).
Determination of HBV infection
HepG2 cells were seeded onto collagen-coated plates (6x105 cells/well) and after 3 days of dif-
ferentiation using 2.5% DMSO infected with HBV (MOI = 100) overnight. Infection was
proven by establishment of nuclear cccDNA and HBeAg secretion. HBeAg was detected in the
culture medium using a commercial immunoassay (Siemens Molecular Diagnostics, Marburg,
Germany). Total DNA was extracted from infected cells 3 days post infection (PI) using a
NucleoSpin tissue kit (Macherey Nagel, Du¨ren, Germany) and subsequently treated with T5
exonuclease (10U/μl) for 10 min before cccDNA detection. HBV cccDNA was detected by real
time PCR (qPCR) with selective PCR primers as previously described [27, 28]. qPCR was per-
formed on the LightCycler 480 real time PCR 96-well system II (Roche, 5015278001) and ana-
lysed using the second derivative maximum approach that takes normalisation to a reference
gene (PrP) and primer efficiency into account.
Immunofluorescence NTCP
HepG2 cells were seeded onto coverslip and cultured using standard culturing conditions
until 60–70% confluence. 72h after seeding, cells were fixed with 3.7% formaldehyde/PBS for
20 min and permeabilized for 2 min with 0.2% Triton X-100/PBS at room temperature. After
rinsing with PBS, nonspecific binding of antibodies was blocked by 2%(w/v) bovine serum
albumin in PBS for 30 minutes at room temperature. Cells were incubated with mouse anti-
HA (H9658, Sigma) for 2 hours followed by Alexa Fluor™ 488-conjugated goat anti-mouse IgG
(Invitrogen) for 45 minutes. Cover slips were washed three times with PBS and Hoechst stain-
ing was performed afterwards. Cells were mounted with mowiol. Images were obtained using
a confocal laser scanning microscope (TCA SP8 X LEICA) equipped with HC Plan Apochro-
mat 63X NA 1,4 oil CS2.
Taurocholate uptake assay
HepG2 cells were seeded into 24-well plates and cultured using standard culturing conditions
until they reached 80% confluence. Cells were rinsed twice with warm uptake buffer [5 mM
KCl, 1.1 mM KH2PO4, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM D-glucose, 10 mM Hepes and
136 mM NaCl]. After which, cells were incubated at 37˚C with uptake buffer containing 20μM
taurocholate supplemented with 0,25μC [3H]taurocholate for 2 min. Subsequently, cells were
washed four times with ice-cold PBS and lysed in 0.05% SDS. Accumulation of radiolabelled
substrates was determined by scintillation counting.
Immunoblotting
Proteins were separated on a 10% polyacrylamide gel and transferred to nitrocellulose mem-
brane. Unspecific binding was blocked with 5% milk in 0.1% TBS-TWEEN (TBST) for 1h at
room temperature. Antibodies for either NTCP (visualized with HA-HRP) or transferrin
receptor (TfR) were added to 5% milk-TBST and incubated with the membrane for 16h at 4˚C
while rocking. After three washes with TBST, membranes were incubated with a HRP (horse-
radish peroxidase)-conjugated mouse antibodies (Sigma) to visualize the TfR as described
Effects of NTCP Glycosylation
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previously [26]. Following three washes in TBST, ECL was performed, and proteins were
detected by chemiluminescence.
Immunoprecipitation
Cells were grown in a 100mm culture plates to 80% confluence. After washing with PBS, cells
were lysed in lysis buffer (150 mM NaCl, 50 mM Tris PH 7,4, 5 mM EDTA, 10% (w/v) sucrose,
1% Nonidet P40) supplemented with protein inhibitors. Subsequently, BCA assay according to
manufactory protocol was performed and equal protein amounts were incubated with mono-
clonal anti-HA antibody (Sigma 9568) immobilized on Protein A—agarose beads (Sigma) for
16h at 4˚C. Samples were analyzed by immunoblotting using anti-HA antibodies (Sigma) and
HRP-conjugated mouse antibodies (Sigma) as described above.
PNGaseF treatment
NTCP was immunoprecipitated from stably transduced HepG2 cells using monoclonal anti-
HA antibody immobilized on Protein A-agarose beads as described above. After addition of
sample buffer (2% (w/v) SDS, 10% v/v glycerol 40mM Tris pH6.8, Bromophenol blue (Sigma
Alrich) containing 0.1M DTT (Promega), supernatant was taken and samples were treated
with PNGase F (peptide N-glycosidase F) according to the manufacturer’s instructions (New
England Biolabs).
Cell surface biotinylation assay
Cells were grown in a 100mm culture plates to 80% confluence. After washing with PBS-CM
(PBS containing 1mM MgCl2, 0.5mM CaCl2, pH 8.0), 0,5mg/ml NHS-ss-Biotin/PBS-CM was
added for 30min at 4˚C. After quenching with PBS-CM containing 0.1% BSA, cells were
washed three times with PBS-CM and lysed in lysis buffer (150 mM NaCl, 50 mM Tris PH 7,4,
5 mM EDTA, 10% (w/v) sucrose, 1% Nonidet P40) supplemented with protein inhibitors.
Lysate was centrifuged and supernatant was added to pre-washed neutravidin beads. Pull
down was performed for 2 hours followed by washing with lysis buffer. The proteins were
eluted in sample buffer and subjected to immunoblotting as described above.
Lysosomal versus proteosomal degradation
Cells were plated for either TCA assay or immunofluorescence as described above. 48 or 66
hours after seeding, treatment with either DMSO, 10nM Bafilomycin (24h) or 20μM MG132
(6h) or a combination of the last two was performed. After treatment, cells were analyzed fol-
lowing the above described protocols.
NTCP plasma membrane expression
Cells were seeded into 96 wells plate (Corning; 734–1609) three days before staining. Cells
were stained with 0.02μM Myrcludex-B—FITC for 30min at 37˚C. Myrcludex B-Fitc intensity
was measured using a NOVOstar microplate reader (BMG Labtech GmbH, Offenburg) at λex
/ λem = 483–14 nm/ 530–30 nm. The option orbital averaging was set at a diameter of 3mm.
Background fluorescence was subtracted and results were plotted as percentage of NTCP WT.
mRNA expression of NTCP
Cells were seeded in a 6 wells format, three days before RNA extraction. Total RNA was
extracted with TRIzol reagent (Invitrogen, Bleiswijk, The Netherlands). Complementary DNA
was synthesized from DNAse-treated total RNA with Oligo-dT12-18 and Superscript II reverse
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transcriptase (Invitrogen). Quantitative real-time polymerase chain reaction (qRT-PCR) was
carried out in a Roche Lightcycler 480 II instrument using SYBR green (Roche) and the
hNTCP primers listed in S2 Table. Expression level in each sample was normalized to refer-
ence gene H36B4.
Statistical analysis
Values are expressed as mean ± sd. Significant analysis was performed using one-way analysis
of variances following the Bonferroni’s multiple comparison test. Graphpad Prism software
was used for analysis.
Supporting Information
S1 Fig. NTCP expression is similar in different cell-lines and not its function is not influ-
enced by the HA-tag. (A) Taurocholate (TCA) uptake assay in parental Huh-7 cells and those
stably expressing NTCP-WT, NTCP-N11Q or NTCP-N5,11Q. Cells were incubated for 2 min-
utes with uptake buffer containing 20 mM taurocholate, spiked with [3H]-taurocholate. NTCP
specific uptake capacity is defined as pmol TCA uptake/well, where the bars represent the
mean +/- sd (n = 4). (B). HepG2 cells, HepaRG cells and Huh-7 cells stably expressing NTCP-
WT were lysed and equal amount of total protein were subjected to immunoblotting for
NTCP either directly or after digestion with PNGase F for 1h at 37˚C (500 units). (C) Tauro-
cholate (TCA) uptake assay in parental HepG2 cells and those stably expressing NTCP-WT or
NTCP-N5,11Q with or without a HA-tag. Cells were incubated for 2 minutes with uptake
buffer containing 20 mM taurocholate, spiked with [3H]-taurocholate. NTCP specific uptake
capacity is defined as pmol TCA uptake/well, where the bars represent the mean +/- sd (n = 4).
(D,E) NTCP mRNA expression (D) and HA-NTCP mRNA expression (E) in HepG2 cells
expressing NTCP-WT or NTCP-N5,11Q with or without a HA-tag analysed by qRT-PCR
using primers listed in S2 Table. NTCP expression values were calculated relative to house-
keeping gene H36B4. Data represent mean +/- SD (N = 4).
(EPS)
S1 Supplementary Methods. HUH-7 cell culture conditions.
(DOC)
S1 Table. Primer sequences used for site-directed mutagenesis to generate single or double
substitution of the two Asn residues (N5 and N11) with glutamine in HA-NTCP by site-
directed mutagenesis.
(DOC)
S2 Table. Oligonucleotide primers used for qRT-PCR to analyze NTCP expression and the
reference gene H36B4.
(DOC)
S3 Table. Overview of the conserved glycosylation sites in SLC10A1 across multiple spe-
cies, including human, mouse, rat, macaca, pongo, and cow and in the related transporter
Slc10A2/ASBT.
(DOC)
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